Medigen

Covid-19 development round-up: March 18, 2022

The state of the fight: 

Medicines Patent Pool sublicensed Pfizer’s Paxlovid to 35 generics manufacturers.
  Key WTO members reached a tentative agreement to waive some IP rights on Covid-19 vaccines.
  Moderna and Pfizer asked the U.S. FDA to authorize fourth doses of their respective jabs.   AUTHORIZED VACCINES

 
Medigen’s protein subunit vaccine (MVC-COV1901) offered similar safety and immunogenicity for adolescents as it did for adults, the Taipei-based…

Mentions:
Covid-19, vaccines, drugs, Medigen, WHO, Moderna, Sinovac, AstraZeneca, FDA, Pfizer, BioNTech, CanSino, Anhui Longcom, Clover, SII, CureVac, GSK, WTO, COVAX, Gamaleya Institute, Gavi, Bio E, J&J, MPP, DNDi, Vir, Merck, Shionogi
Read more
Covid-19 development round-up: February 18, 2022

The state of the fight: 

Moderna applied for South African patents on its vaccine, potentially jeopardizing the work of the WHO-led mRNA vaccine “hub” operating in the country.
  WHO named five additional African countries that will receive vaccine technology from the hub.
  Laboratorios Farmacéuticos Rovi inked a 10-year mRNA vaccine manufacturing extension with Moderna.   AUTHORIZED VACCINES

                                       
Medigen’s protein subunit…

Mentions:
Covid-19, vaccines, drugs, Medigen, AstraZeneca, Biological E, Moderna, Novavax, Abogen, Walvax, Gamaleya Institute, WHO, Afrigen, Pfizer, BioNTech, COVAX, Gavi, Merck, Gilead, Roche, Shionogi
Read more
Covid-19 development round-up: January 29, 2021

The state of the hunt:

Novavax’s protein-based vaccine candidate demonstrated 89.3% efficacy in a UK Phase 3 trial.
  J&J/Janssen’s single-dose vaccine was 66% effective against moderate to severe disease in Phase 3.
  Vaccines from J&J, Moderna, Novavax and Pfizer/BioNTech appear less effective against the SARS-CoV-2 variant first identified in South Africa.

 

Vaccines


Approved or authorized vaccines

AstraZeneca/Oxford’s…

Mentions:
Novavax, J&J, Janssen, Moderna, Pfizer, BioNTech, EMA, AstraZeneca, Oxford, SII, WHO, SAGE, Fosun, EU, Gamaleya Institute, CNBG, Sinopharm, Sinovac, BBIL, FDA, Imperial College London, Medigen, Dynavax, Providence Therapeutics, Merck, IAVI, Mass General Brigham, Penn Medicine, BMGF, GI-Cell, IVI, EC, Daiichi Sankyo, JCR Pharmaceuticals, CSL, Sanofi, Novartis, Africa CDC, Lonza, COVAX Facility, Pharmaniaga, Duopharma, AVATT, Valneva, COVAX, UNICEF, CEPI, DP World, FEMA, DoD, CDC, BIBP, Regeneron, Lilly, Vir, GSK, NIH, Zydus Cadila, Rigel Pharmaceuticals, Dr. Reddy’s, Fujifilm, Just-Evotec, Humanigen, BARDA, Emergent, Ajinomoto, Shionogi, Bioage Labs, Pulmotect, Civica Rx
Read more
Vaxess wins $2M for mRNA vaccines

Vaxess announced last week that the National Science Foundation and the U.S. Defense Advanced Research Projects Agency have awarded the Massachusetts company up to $2 million to develop mRNA-based vaccines and “other medical countermeasures.” The projects will use the company’s MIMIX smart release patch technology to develop refrigeration-free, single-dose products.

Vaxess has several deals in the works for its MIMIX technology, including a collaboration with GC Pharma to combine the…

Mentions:
Vaxess, NSF, DARPA, vaccines, MAP, GC Pharma, flu, Medigen, Covid-19
Read more
Covid-19 development round-up: January 8, 2021

The state of the hunt:

WHO issued its first EUL for a Covid-19 vaccine in recent days while Britain and the EMA authorized an additional jab and China and India cleared their first shots.
  Both Bharat Biotech and Pfizer claimed their respective vaccines are effective against newly identified SARS-CoV-2 variants.
  SII pledged to sell an initial 100 million doses to India at a “special price” of $2.74 each.

 

Vaccines


Approved or authorized…

Mentions:
Covid-19, vaccines, drugs, WHO, EMA, SII, COVAX Facility, AstraZeneca, Oswaldo Cruz Foundation, Fiocruz, CNBG, BIBP, Sinopharm, Moderna, Pfizer, BioNTech, BBIL, Gamaleya Institute, União Química Farmacêutica Nacional, CureVac, Bayer, Sinovac, halal, Zydus Cadila, Inovio, Advaccine, Cellid, IVI, ReiThera, StemiRNA, Tibet Rhodiola, Medigen, Arcturus, IDT Biologika, DZIF, Akston Biosciences, LakePharma, Oragenics, Adjuvance, Emergex, Bio-Manguinhos, Intravacc, Cristal Therapeutics, University of Oxford, Trilink, Aldevron, New England Biolabs, Lonza, EC, Bio Farma, Novavax, J&J, Janssen, Hindustan Syringes, PATH, UNICEF, Wuxi Yushou Medical Appliances, COVAX, SAGE, CDC, Roche, Regeneron, Daewoong Pharmaceuticals, Navin Saxena, Gilead, Brii Biosciences, aTyr Pharma, Creative Medical Technology Holdings, NIH, Emergent, Mount Sinai Health System, DoD
Read more
Covid-19 development round-up: October 16, 2020

The state of the hunt:

Remdesivir showed “little or no effect” on 28-day mortality or the duration of hospital stay among hospitalized Covid-19 patients, according to data from a WHO study.
  J&J paused all dosing in trials involving its Janssen subsidiary’s vaccine candidate.
  Pfizer will not apply for U.S. FDA Emergency Use Authorization for its mRNA Covid-19 vaccine candidate before the third week of November.

 

Vaccines

Phase 3 candidates:…

Mentions:
Covid-19, vaccines, drugs, diagnostics, Gilead, WHO, Pfizer, BioNTech, mRNA, J&J, Janssen, Vector Center, AstraZeneca, SII, CNBG, RDIF, Dr. Reddy’s Laboratories, Sinovac, BBIL, IDT Biologika, DZIF, Imperial College London, Medigen, Dynavax, Vaxart, ImmunityBio, Siam Bioscience, CanSino, TTY Biopharm, CEPI, Bio Farma, Cytiva, BARDA, Epygen, Dyadic, EuBiologics, NIH, CDC, IMV, Translate Bio, Sanofi, Gavi, COVAX, DARPA, Moderna, Novavax, NIAID, Fujifilm Toyama, Recipharm, Daewoong, Merck, Lilly, Celltrion, Apogenix, Enlivex, Cue Health, DoD, Roche, Siemens, Africa CDC, BMGF, ICER
Read more
Covid-19 development round-up: September 18, 2020

The state of the hunt:

Phase 3 trials of AstraZeneca’s AZD1222 vaccine candidate resumed in Brazil, Britain, India and South Africa, while U.S. officials voiced safety concerns.
  The United Arab Emirates joined China in issuing emergency approval of a CNBG inactivated vaccine candidate.
  A trial of Lilly’s RA drug Olumiant in combination with remdesivir met its primary endpoint.

 

Vaccines

Phase 3 candidates:
 
Phase 3 trials resumed last…

Mentions:
Covid-19, vaccines, drugs, diagnostics, AstraZeneca, CNBG, Lilly, Imperial College London, Pfizer, BioNTech, mRNA, Moderna, Dr. Reddy’s, Gamaleya, RDIF, Sinovac, CanSino, Vaxart, Brickell Biotech, PharmaJet, Genexine, WHO, COVAX, Gavi, CEPI, EC, EU, COVAX AMC, Novavax, SII, Valneva, Dynavax, Sanofi, GSK, Novartis, R-Pharm, Ology Bioservices, BARDA, Aurobindo, BIRAC, NII, Vaxess, Medigen, MAP, Ufovax, Fiocruz, IVI, BMGF, Gilead, mAbs, Roche, Genentech, Rigel, Starpharma, Amgen, Regeneron, Takeda, NIAID, InflaRx, Lonza, Humanigen, Celltrion, Kiadis Pharma, PNB Vesper, Senwha, Tiziana, Allovir, Baylor, BGI, PerkinElmer, Siemens Healthineers, CDC, NIH
Read more
Covid-19 development round-up: July 24, 2020

The state of the hunt:

The EU is reportedly weighing abstention from the COVAX Facility due to vaccine pricing and timing concerns.
  An inhaled interferon drug produced extraordinary Phase 2 data in a study some critics have faulted.
  Vaccines from AstraZeneca-Oxford University, CanSino, and Pfizer-BioNTech had positive Phase 1/2 or Phase 2 news.

 

Vaccines

Clinical trials:

The Lancet published preliminary Phase 1/2 results Monday showing the…

Mentions:
Covid-19, vaccines, drugs, diagnostics, COVAX, AstraZeneca, Oxford, CanSino, Pfizer, BioNTech, Synairgen, SII, CNBG, Bio Farma, Arcturus, Gennova, Valneva, SK Bioscience, R-Pharm, Shionogi, Fujifilm Diosynth, Novavax, Altimmune, Vigene, Dynavax, Medigen, mRNA, Beijing Institute of Microbiology and Epidemiology, WHO, EU, CEPI, Mount Sinai, Moderna, Arbutus, InflaRx, RedHill, Sorrento, ACEA, Merck, IRBM, Innovation Pharmaceuticals, mAbs, Fujifilm Toyama Chemical, Glenmark, Zydus Cadila, 60 Degrees Pharmaceuticals, Africa CDC, DOJ, AbCellera, Amgen, Eli Lilly, GSK, Roche, Genentech, FDA, EMA, Quest Diagnostics, Utrecht University
Read more
Subscribe to Medigen